Drug Approval | May 06, 2024
Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
The project funding will be done through a mix of internal accruals and debts.
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Subscribe To Our Newsletter & Stay Updated
